Colfax Corporation
| NYSE: CFX |
| Industrials / Industrial Products / USA |
| 39.06 | 0 | 0.00 | Vol - | 1Y Perf -9.75% |
| Apr 4th, 2022 16:00 DELAYED |
| BID | 0.00 | ASK | 0.00 | ||
| Open | 0.00 | Previous Close | 39.06 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 51.11 | Analyst Rating | — — 0.00 | |
| Potential % | - | Finscreener Ranking | ★★+ — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★+ — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★ — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 0.00 | Earnings Rating | Buy | |
| Market Cap | 2.10B | Earnings Date | 5th May 2022 | |
| Alpha | -0.02 | Standard Deviation | 0.12 | |
| Beta | 2.13 |
Today's Price Range 0.000.00 | 52W Range -186.13-131.00 | 5 Year PE Ratio Range -3.20176.40 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | - | ||
| 1 Month | 0.00% | ||
| 3 Months | -5.49% | ||
| 6 Months | -23.38% | ||
| 1 Year | -9.75% | ||
| 3 Years | 45.20% | ||
| 5 Years | -1.51% | ||
| 10 Years | 45.20% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -2.36 | |||
ROE last 12 Months | 1.76 | |||
ROA (5Y Avg) | -1.04 | |||
ROA last 12 Months | 0.90 | |||
ROC (5Y Avg) | 0.35 | |||
ROC last 12 Months | 1.79 | |||
Return on invested Capital Q | 0.14 | |||
Return on invested Capital Y | 0.14 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 2.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 90.20 | ||||
| 1.42 | ||||
| 0.71 | ||||
| 17.70 | ||||
| 90.70 | ||||
| 2.29 | ||||
| -12.46 | ||||
| 28.62 | ||||
| 8.10B | ||||
| Forward PE | 14.57 | |||
| PEG | 4.27 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.30 | ||||
| 2.30 | ||||
| 0.33 | ||||
| 0.49 | ||||
| 3.30 | ||||
| Leverage Ratio | 1.80 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 41.90 | ||||
| 6.20 | ||||
| 13.00 | ||||
| 2.40 | ||||
| 1.88 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 2.98B | ||||
| 55.32 | ||||
| -1.25 | ||||
| -0.29 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2021 | 0.57 | 0.59 | 3.51 |
| Q03 2021 | 0.54 | 0.54 | 0.00 |
| Q02 2021 | 0.53 | 0.56 | 5.66 |
| Q01 2021 | 0.39 | 0.44 | 12.82 |
| Q04 2020 | 0.49 | 0.51 | 4.08 |
| Q03 2020 | 0.40 | 0.41 | 2.50 |
| Q02 2020 | 0.06 | 0.09 | 50.00 |
| Q01 2020 | 0.37 | 0.38 | 2.70 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2022 QR | 0.49 | -15.52 | Negative |
| 6/2022 QR | 0.60 | -13.04 | Negative |
| 12/2022 FY | 2.39 | -6.64 | Negative |
| 12/2023 FY | 2.68 | -6.94 | Negative |
| Next Report Date | - |
| Estimated EPS Next Report | 0.49 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 0 |
| Shares Outstanding | 53.78K |
| Shares Float | 136.18M |
| Trades Count | 0 |
| Dollar Volume | 0 |
| Avg. Volume | 1.29M |
| Avg. Weekly Volume | 0 |
| Avg. Monthly Volume | 0 |
| Avg. Quarterly Volume | 1.29M |
Colfax Corporation (NYSE: CFX) stock closed at 39.06 per share at the end of the most recent trading day (a -3% change compared to the prior day closing price) with a volume of 21.38K shares and market capitalization of 2.10B. Is a component of Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Industrial Products industry, Industrials sector and employs 15400 people. Colfax Corporation CEO is Matthew L. Trerotola.
The one-year performance of Colfax Corporation stock is -9.75%, while year-to-date (YTD) performance is -15.03%. CFX stock has a five-year performance of -1.51%. Its 52-week range is between -186.130842 and -130.999218, which gives CFX stock a 52-week price range ratio of %
Colfax Corporation currently has a PE ratio of 90.20, a price-to-book (PB) ratio of 1.42, a price-to-sale (PS) ratio of 0.71, a price to cashflow ratio of 17.70, a PEG ratio of 2.32, a ROA of 0.90%, a ROC of 1.79% and a ROE of 1.76%. The company’s profit margin is 1.88%, its EBITDA margin is 13.00%, and its revenue ttm is $2.98 Billion , which makes it $55.32 revenue per share.
Of the last four earnings reports from Colfax Corporation, there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.49 for the next earnings report. Colfax Corporation’s next earnings report date is -.
The consensus rating of Wall Street analysts for Colfax Corporation is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Colfax Corporation stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Colfax Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Colfax Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 22.02, ATR14 : 1.29, CCI20 : 17.90, Chaikin Money Flow : 0.10, MACD : -0.07, Money Flow Index : 49.91, ROC : -2.76, RSI : 49.31, STOCH (14,3) : 35.99, STOCH RSI : 0.20, UO : 42.18, Williams %R : -64.01), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Colfax Corporation in the last 12-months were:
Colfax Corporation
Colfax is a diversified technology firm that produces welding equipment and medical devices. Following the sale of its air and gas handling business in 2019, Colfax's remaining portfolio is organized into two segments: fabrication technology and medical technology. Fabrication technology is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications, mostly marketed under the ESAB brand name. The medical technology segment makes medical devices, including orthopedic braces, reconstructive implants, and other products used for rehabilitation, physical therapy, and pain management. The company generated roughly $3.1 billion in revenue in 2020.
CEO: Matthew L. Trerotola
Telephone: +1 301 323-9000
Address: 420 National Business Parkway, Annapolis Junction 20701, MD, US
Number of employees: 15 400
TipRanks News for CFX
Sun, 03 Apr 2022 16:43 GMT Colfax (CFX) Receives a Buy from Robert W. Baird
- TipRanks. All rights reserved.
